HER2--话题@MedSci

#HER2-#

66篇内容 | 1326人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1982561, encodeId=6a74198256194, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, objectTitle=Lancet Oncol：氟维司群联合Capivasertib治疗芳香化酶抑制剂耐药性晚期/复发性ER+HER2-乳腺癌, objectType=article, longId=729208, objectId=e8d9e29208b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8d9e29208b5, replyNumber=0, likeNumber=65, createdTime=2023-03-01, rootId=0, userName=luwei00, userId=e093393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8d9e29208b5, moduleTitle=Lancet Oncol：氟维司群联合Capivasertib治疗芳香化酶抑制剂耐药性晚期/复发性ER+HER2-乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8d9e29208b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1982554, encodeId=672f198255415, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, objectTitle=Clin Cancer Res：Palbociclib联合氟维司群治疗HR+/HER2-晚期乳腺癌的长期预后, objectType=article, longId=727037, objectId=b5dce27037f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5dce27037f6, replyNumber=0, likeNumber=42, createdTime=2023-04-26, rootId=0, userName=luwei00, userId=e093393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5dce27037f6, moduleTitle=Clin Cancer Res：Palbociclib联合氟维司群治疗HR+/HER2-晚期乳腺癌的长期预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b5dce27037f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1982559, encodeId=98491982559e8, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, objectTitle=ASCO2022 | 里程碑式突破！DESTINYBreast04结果显示，T-DXd对HER2-低表达mBC安全有效！, objectType=article, longId=728766, objectId=ebf0e2876637, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ebf0e2876637, replyNumber=0, likeNumber=42, createdTime=2022-12-19, rootId=0, userName=luwei00, userId=e093393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ebf0e2876637, moduleTitle=ASCO2022 | 里程碑式突破！DESTINYBreast04结果显示，T-DXd对HER2-低表达mBC安全有效！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ebf0e2876637)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1982562, encodeId=42c6198256285, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, objectTitle=HR+HER2-晚期乳腺癌CDK4/6i失败后治疗模式新探索, objectType=article, longId=736714, objectId=1cd4e36714ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1cd4e36714ec, replyNumber=0, likeNumber=57, createdTime=2022-11-13, rootId=0, userName=luwei00, userId=e093393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1cd4e36714ec, moduleTitle=HR+HER2-晚期乳腺癌CDK4/6i失败后治疗模式新探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1cd4e36714ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1982549, encodeId=6171198254915, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, objectTitle=Clin Cancer Res：mTOR抑制剂sapanisertib联合氟维司群治疗芳香化酶抑制剂进展后ER+/ HER2-的绝经后女性晚期乳腺癌患者的疗效, objectType=article, longId=293538, objectId=db002935384a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db002935384a, replyNumber=0, likeNumber=0, createdTime=2022-01-26, rootId=0, userName=luwei00, userId=e093393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db002935384a, moduleTitle=Clin Cancer Res：mTOR抑制剂sapanisertib联合氟维司群治疗芳香化酶抑制剂进展后ER+/ HER2-的绝经后女性晚期乳腺癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db002935384a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1982550, encodeId=acb01982550f2, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, objectTitle=Front Oncol：回顾性研究比较白蛋白结合紫杉醇和多西他赛作为新辅助治疗治疗HER2-乳腺癌患者的疗效, objectType=article, longId=293860, objectId=16d129386032, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16d129386032, replyNumber=0, likeNumber=40, createdTime=2022-10-11, rootId=0, userName=luwei00, userId=e093393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16d129386032, moduleTitle=Front Oncol：回顾性研究比较白蛋白结合紫杉醇和多西他赛作为新辅助治疗治疗HER2-乳腺癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16d129386032)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1982563, encodeId=d7fc1982563c1, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, objectTitle=ESMO 2022：Sacituzumab Govitecan-hziy在HER2-低表达/HER2-0转移性乳腺癌中显示出有前景的疗效（TROPiCS-02研究）, objectType=article, longId=739076, objectId=83fde390764d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83fde390764d, replyNumber=0, likeNumber=49, createdTime=2023-05-18, rootId=0, userName=luwei00, userId=e093393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83fde390764d, moduleTitle=ESMO 2022：Sacituzumab Govitecan-hziy在HER2-低表达/HER2-0转移性乳腺癌中显示出有前景的疗效（TROPiCS-02研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83fde390764d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1982557, encodeId=4ba4198255ec6, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, objectTitle=2022 ASCO：内分泌疗法±辅助化疗治疗ER+HER2-老年乳腺癌患者的长期预后, objectType=article, longId=728383, objectId=8dade283838d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8dade283838d, replyNumber=0, likeNumber=58, createdTime=2022-11-06, rootId=0, userName=luwei00, userId=e093393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8dade283838d, moduleTitle=2022 ASCO：内分泌疗法±辅助化疗治疗ER+HER2-老年乳腺癌患者的长期预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8dade283838d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1982556, encodeId=fe0a1982556fd, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, objectTitle=JCO：口服SERD艾拉司群治疗ER+/HER2-晚期乳腺癌安全有效！EMERALD III期临床最新数据出炉！, objectType=article, longId=727998, objectId=c0e7e2799863, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0e7e2799863, replyNumber=0, likeNumber=55, createdTime=2023-01-31, rootId=0, userName=luwei00, userId=e093393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0e7e2799863, moduleTitle=JCO：口服SERD艾拉司群治疗ER+/HER2-晚期乳腺癌安全有效！EMERALD III期临床最新数据出炉！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0e7e2799863)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1982560, encodeId=b4451982560cf, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, objectTitle=ASCO2022 | TROPiCS-02临床重磅发布：戈沙妥珠单抗使HR+/HER2-MBC进展或死亡降低34%！, objectType=article, longId=728853, objectId=14b5e2885349, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14b5e2885349, replyNumber=0, likeNumber=44, createdTime=2023-04-13, rootId=0, userName=luwei00, userId=e093393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14b5e2885349, moduleTitle=ASCO2022 | TROPiCS-02临床重磅发布：戈沙妥珠单抗使HR+/HER2-MBC进展或死亡降低34%！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14b5e2885349)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1982544, encodeId=cec51982544e5, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, objectTitle=Front Oncol：ER+/HER2-且淋巴结阳性的绝经前乳腺癌患者，新辅助化疗（NCT）对比新辅助内分泌治疗（NET）的疗效：III期临床研究NEST , objectType=article, longId=218140, objectId=973121814015, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=973121814015, replyNumber=0, likeNumber=35, createdTime=2022-04-03, rootId=0, userName=luwei00, userId=e093393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=973121814015, moduleTitle=Front Oncol：ER+/HER2-且淋巴结阳性的绝经前乳腺癌患者，新辅助化疗（NCT）对比新辅助内分泌治疗（NET）的疗效：III期临床研究NEST , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=973121814015)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1982551, encodeId=a770198255155, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, objectTitle=Eur J Cancer：Palbociclib或安慰剂联合氟维司群治疗HR+/HER2-晚期乳腺癌患者的疗效, objectType=article, longId=293782, objectId=8b44293e82df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b44293e82df, replyNumber=0, likeNumber=40, createdTime=2022-04-22, rootId=0, userName=luwei00, userId=e093393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b44293e82df, moduleTitle=Eur J Cancer：Palbociclib或安慰剂联合氟维司群治疗HR+/HER2-晚期乳腺癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b44293e82df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1982552, encodeId=dfb11982552d2, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, objectTitle=Front Oncol：徐兵河院士团队发现HER2-乳腺癌中HER2低表达可能是预后良好指标, objectType=article, longId=294156, objectId=e468294156ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e468294156ec, replyNumber=0, likeNumber=55, createdTime=2022-07-21, rootId=0, userName=luwei00, userId=e093393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e468294156ec, moduleTitle=Front Oncol：徐兵河院士团队发现HER2-乳腺癌中HER2低表达可能是预后良好指标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e468294156ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1982543, encodeId=649619825431e, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, objectTitle=Breast Cancer Res ：阿贝西利（Abemaciclib）联合氟维司群治疗绝经前女性HR+/HER2-的晚期乳腺癌疗效:来自MONARCH 2试验的亚组分析, objectType=article, longId=218041, objectId=1ce121804150, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ce121804150, replyNumber=0, likeNumber=41, createdTime=2022-08-29, rootId=0, userName=luwei00, userId=e093393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ce121804150, moduleTitle=Breast Cancer Res ：阿贝西利（Abemaciclib）联合氟维司群治疗绝经前女性HR+/HER2-的晚期乳腺癌疗效:来自MONARCH 2试验的亚组分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ce121804150)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1982546, encodeId=2502198254689, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, objectTitle=Nat Med： Dalpiciclib（达尔西利）或安慰剂+氟维司群治疗HR+/HER2-晚期乳腺癌的疗效和安全性对比：Ⅲ期DAWNA-1研究, objectType=article, longId=220818, objectId=b1cd22081859, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1cd22081859, replyNumber=0, likeNumber=0, createdTime=2022-01-17, rootId=0, userName=luwei00, userId=e093393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1cd22081859, moduleTitle=Nat Med： Dalpiciclib（达尔西利）或安慰剂+氟维司群治疗HR+/HER2-晚期乳腺癌的疗效和安全性对比：Ⅲ期DAWNA-1研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1cd22081859)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1982555, encodeId=2144198255519, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, objectTitle=J Clin Oncol：Elacestrant vs 标准内分泌疗法治疗ER+/HER2-晚期乳腺癌, objectType=article, longId=727470, objectId=49e6e27470b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49e6e27470b5, replyNumber=0, likeNumber=0, createdTime=2022-12-02, rootId=0, userName=luwei00, userId=e093393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49e6e27470b5, moduleTitle=J Clin Oncol：Elacestrant vs 标准内分泌疗法治疗ER+/HER2-晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49e6e27470b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1982558, encodeId=a5de19825585c, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, objectTitle=NEJM：新型HER2-ADC Enhertu打破HER2低表达的乳腺癌治疗困境（DESTINY-Breast04）, objectType=article, longId=728825, objectId=0933e28825b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0933e28825b2, replyNumber=0, likeNumber=55, createdTime=2022-08-13, rootId=0, userName=luwei00, userId=e093393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0933e28825b2, moduleTitle=NEJM：新型HER2-ADC Enhertu打破HER2低表达的乳腺癌治疗困境（DESTINY-Breast04）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0933e28825b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1982548, encodeId=281f19825486e, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, objectTitle=Clin Cancer Res：MONALEESA-7研究更新结果表明瑞博西尼（Ribociclib）联合内分泌治疗较内分泌单药持续改善HR+/HER2- 晚期乳腺癌患者的预后, objectType=article, longId=293536, objectId=393e293536fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=393e293536fe, replyNumber=0, likeNumber=51, createdTime=2022-09-08, rootId=0, userName=luwei00, userId=e093393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=393e293536fe, moduleTitle=Clin Cancer Res：MONALEESA-7研究更新结果表明瑞博西尼（Ribociclib）联合内分泌治疗较内分泌单药持续改善HR+/HER2- 晚期乳腺癌患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=393e293536fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1982540, encodeId=0ac31982540e7, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, objectTitle=Clin Cancer Res:瑞博西尼（ribociclib）联合依西美坦+依维莫司治疗CDK4/6抑制剂治疗进展的HR+/HER2-晚期乳腺癌的疗效和安全性：I/II期TRINITI-1研究, objectType=article, longId=213367, objectId=676e21336e25, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=676e21336e25, replyNumber=0, likeNumber=45, createdTime=2021-09-17, rootId=0, userName=luwei00, userId=e093393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=676e21336e25, moduleTitle=Clin Cancer Res:瑞博西尼（ribociclib）联合依西美坦+依维莫司治疗CDK4/6抑制剂治疗进展的HR+/HER2-晚期乳腺癌的疗效和安全性：I/II期TRINITI-1研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=676e21336e25)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1982553, encodeId=b34919825530b, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, objectTitle=Eur J Cancer：来曲唑+帕博西尼新辅助治疗或可替代高危型ER+HER2-乳腺癌的化疗, objectType=article, longId=301809, objectId=25d630180953, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25d630180953, replyNumber=0, likeNumber=44, createdTime=2022-07-29, rootId=0, userName=luwei00, userId=e093393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25d630180953, moduleTitle=Eur J Cancer：来曲唑+帕博西尼新辅助治疗或可替代高危型ER+HER2-乳腺癌的化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25d630180953)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

HER2-

2020-05-29

luwei00 (审核中...)

前往app查看评论内容

#HER2-#

Lancet Oncol：氟维司群联合Capivasertib治疗芳香化酶抑制剂耐药性晚期/复发性ER+HER2-乳腺癌

2023-03-01

luwei00 (审核中...)

前往app查看评论内容

#HER2-#

Clin Cancer Res：Palbociclib联合氟维司群治疗HR+/HER2-晚期乳腺癌的长期预后

2023-04-26

luwei00 (审核中...)

前往app查看评论内容

#HER2-#

ASCO2022 | 里程碑式突破！DESTINYBreast04结果显示，T-DXd对HER2-低表达mBC安全有效！

2022-12-19

luwei00 (审核中...)

前往app查看评论内容

#HER2-#

HR+HER2-晚期乳腺癌CDK4/6i失败后治疗模式新探索

2022-11-13

luwei00 (审核中...)

前往app查看评论内容

#HER2-#

Clin Cancer Res：mTOR抑制剂sapanisertib联合氟维司群治疗芳香化酶抑制剂进展后ER+/ HER2-的绝经后女性晚期乳腺癌患者的疗效

2022-01-26

luwei00 (审核中...)

前往app查看评论内容

#HER2-#

Front Oncol：回顾性研究比较白蛋白结合紫杉醇和多西他赛作为新辅助治疗治疗HER2-乳腺癌患者的疗效

2022-10-11

luwei00 (审核中...)

前往app查看评论内容

#HER2-#

ESMO 2022：Sacituzumab Govitecan-hziy在HER2-低表达/HER2-0转移性乳腺癌中显示出有前景的疗效（TROPiCS-02研究）

2023-05-18

luwei00 (审核中...)

前往app查看评论内容

#HER2-#

2022 ASCO：内分泌疗法±辅助化疗治疗ER+HER2-老年乳腺癌患者的长期预后

2022-11-06

luwei00 (审核中...)

前往app查看评论内容

#HER2-#

JCO：口服SERD艾拉司群治疗ER+/HER2-晚期乳腺癌安全有效！EMERALD III期临床最新数据出炉！

2023-01-31

luwei00 (审核中...)

前往app查看评论内容

#HER2-#

ASCO2022 | TROPiCS-02临床重磅发布：戈沙妥珠单抗使HR+/HER2-MBC进展或死亡降低34%！

2023-04-13

luwei00 (审核中...)

前往app查看评论内容

#HER2-#

Front Oncol：ER+/HER2-且淋巴结阳性的绝经前乳腺癌患者，新辅助化疗（NCT）对比新辅助内分泌治疗（NET）的疗效：III期临床研究NEST

2022-04-03

luwei00 (审核中...)

前往app查看评论内容

#HER2-#

Eur J Cancer：Palbociclib或安慰剂联合氟维司群治疗HR+/HER2-晚期乳腺癌患者的疗效

2022-04-22

luwei00 (审核中...)

前往app查看评论内容

#HER2-#

Front Oncol：徐兵河院士团队发现HER2-乳腺癌中HER2低表达可能是预后良好指标

2022-07-21

luwei00 (审核中...)

前往app查看评论内容

#HER2-#

Breast Cancer Res ：阿贝西利（Abemaciclib）联合氟维司群治疗绝经前女性HR+/HER2-的晚期乳腺癌疗效:来自MONARCH 2试验的亚组分析

2022-08-29

luwei00 (审核中...)

前往app查看评论内容

#HER2-#

Nat Med： Dalpiciclib（达尔西利）或安慰剂+氟维司群治疗HR+/HER2-晚期乳腺癌的疗效和安全性对比：Ⅲ期DAWNA-1研究

2022-01-17

luwei00 (审核中...)

前往app查看评论内容

#HER2-#

J Clin Oncol：Elacestrant vs 标准内分泌疗法治疗ER+/HER2-晚期乳腺癌

2022-12-02

luwei00 (审核中...)

前往app查看评论内容

#HER2-#

NEJM：新型HER2-ADC Enhertu打破HER2低表达的乳腺癌治疗困境（DESTINY-Breast04）

2022-08-13

luwei00 (审核中...)

前往app查看评论内容

#HER2-#

Clin Cancer Res：MONALEESA-7研究更新结果表明瑞博西尼（Ribociclib）联合内分泌治疗较内分泌单药持续改善HR+/HER2- 晚期乳腺癌患者的预后

2022-09-08

luwei00 (审核中...)

前往app查看评论内容

#HER2-#

Clin Cancer Res:瑞博西尼（ribociclib）联合依西美坦+依维莫司治疗CDK4/6抑制剂治疗进展的HR+/HER2-晚期乳腺癌的疗效和安全性：I/II期TRINITI-1研究

2021-09-17

luwei00 (审核中...)

前往app查看评论内容

#HER2-#

Eur J Cancer：来曲唑+帕博西尼新辅助治疗或可替代高危型ER+HER2-乳腺癌的化疗

2022-07-29

科室
- - 订阅+
  - 更多科室
工具
服务